Latest Protein kinase inhibitor Stories
- Results from two large trials individually showed an improvement in the secondary endpoint of overall survival for patients with the most common EGFR mutation (Del19) RIDGEFIELD, Conn., Jan.
-Profile Supports Potential Role in Modulating Tumor Microenvironment in Blood-Related Cancers, Including AML, MDS, CMML and CLL- SEATTLE, Dec.
- Update on complete remissions with personalized cell therapy CTL019 in patients with relapsed/refractory acute lymphoblastic leukemia EAST HANOVER, N.J., Dec.
- Builds on Company's novel discovery of several kinase fusion genes in cancer - CAMBRIDGE, Mass., Nov.
-Proceeds to support continued advancement of highly selective kinase inhibitors to genomically defined cancers, including first-in-class FGFR4 and KIT Exon 17 inhibitors- CAMBRIDGE, Mass.,
LONDON and SUNNYVALE, Calif., Nov. 4, 2014 /PRNewswire/ -- AstraZeneca and Pharmacyclics, Inc.
Launch of Four Novel Immune Checkpoint Inhibitors Will Be the Major Driver of Growth, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct.
-- LUME-COLON 1 will evaluate the efficacy and safety of nintedanib in specific patients with metastatic colorectal cancer (mCRC) whose disease has progressed on previous treatment
Launch of Novel Immune Checkpoint Inhibitors Will Fuel Market Growth and Will Dramatically Enhance RCC Treatment Algorithm, According to Findings from Decision Resources Group BURLINGTON, Mass.,
WOODCLIFF LAKE, N.J., Oct. 14, 2014 /PRNewswire/ -- Eisai Inc. announced today that the U.S.
- An imitative word; an onomatopoetic word.